Dry AMD Clinical Trial
Official title:
Evaluation of Macular Function and Related Changes in Visual Perception and Retinal Morphology After 6 Months of Use of Oral Supplementation Called MACUPREV, in Patients With Dry Age-related Macular Degeneration (AMD)
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed
and therefore an increase in the production of free radicals responsible for tissue damage.
The Age-Related Eye Disease Study (AREDS) found that the intake of antioxidants reduces the
risk of progression of the disease to an advanced stage (choroidal neovascularization or
geographic atrophy ) and reduces the loss of visual acuity.
In this study the investigators want to analyze the functional retinal changes (mfERG) of the
macular region, in patients with dry age-related macular degeneration, after the use for 6
months of an oral supplementation based on Ganoderma lucidum (Reishi), Calendula Officinalis,
Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid,
Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03297515 -
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
|
N/A | |
| Terminated |
NCT00307398 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 |